Loading company…
BinHui Biotech, established in 2010 in Wuhan, develops oncolytic virus immunotherapies, with its lead product in US clinical trials.
Established in 2010 and based in Wuhan, China, BinHui Biotech focuses on oncolytic virus immunotherapy. Founder and chairman Binlei Liu holds a PhD in molecular viruses from the University of Southampton. Its oHSV2 platform kills tumor cells directly and triggers immune responses, and its first product has three IND approvals for oncolytic virus monotherapy and combination therapies. The company has partnerships with Atagenix, Hong Tough Pharmaceuticals and Sugar Smart Pharmaceuticals and closed a strategic funding round in April 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in